Prof. Mehmet Haberal is presented with The Award of The Spanish Order of The Civil Merit (Cruz de Official) by His Majesty King Felipe VI, King of Spain.
We are honored to announce that Prof. Dr. Seza Özen who is the member of Honorary Advisory Board of JBACHS has already won the Aziz Sancar Science Award of TUSEB.
We are happy to announce that The Journal of Basic and Clinical Health Sciences (JBACHS) is indexed by the Emerging Sources Citation Index since November 2017, and indexed by the Ulakbim-TR since 2017.
Journal of Basic and Clinical Health Sciences 2019 , Vol 3 , Issue 2
Anticancer Efficiency of Curcumin on Ovarian Cancer
Gizem Calibasi Kocal1
1Dokuz Eylul University, Institute of Oncology, Department of Translational Oncology, Izmir, Turkey DOI : 10.30621/jbachs.2019.610 Objectives: Ovarian cancer is one of the most common malignancies in women, and it is quite difficult to cure. In order to treat the disease, chemotherapy is often performed as adjuvant therapy following the surgery or neo-adjuvant cure for the pre-operative purpose. While the strategy is an effective way to destroy the tumor, it also affects healthy cells thus it causes side effects leading to even multiple organ failure and death. So that to minimize the disadvantage of chemotherapeutics, phytochemicals have been studied as chemotherapeutic agents. Curcumin is an orange-yellow nutraceutical, which is isolated from turmeric (Curcuma longa L.). This phyto-polyphenolic compound has various roles in bio-industry such as textile and food dye as well as a wide range of medicinal properties especially the anticancer feature.

Methods: The aim of this study is to investigate the anti-proliferative and anti-migrative effects of curcumin on ovarian adenocarcinoma. Cell proliferation rates on ONCO-DG-1 cell line were examined in five different doses of curcumin. Wound healing assay was performed to evaluate the anti-migrative effect on curcumin on this cell line.

Results: The results showed that curcumin inhibits tumor cell proliferation at 5, 10, 20, 30 and 40 μM doses at 24- and 48-hours incubation time (p<0.05). IC50 dose of curcumin is determined as 17 μM on ONCO-DG-1 cell line. Wound healing assays showed that curcumin inhibits the wound closure with its anti-migrative effect on ONCO-DG-1 cell line.

Conclusion: Due to the anticancer features of curcumin, it can be considered as a promising chemotherapeutic agent in the treatment of ovarian adenocarcinoma. Keywords : Curcumin, Ovarian Cancer, Anticancer, Antiproliferative, Antimigrative, ONCO-DG-1